Department of Gastrointestinal Oncology, Osaka International Cancer Institute, Osaka, Japan.
Department of Genetic Oncology, Division of Hereditary Tumors, Osaka International Cancer Institute, Osaka, Japan.
Cancer Sci. 2023 Dec;114(12):4596-4606. doi: 10.1111/cas.15945. Epub 2023 Oct 5.
Familial adenomatous polyposis (FAP) patients develop various life-threatening extracolonic comorbidities that appear individually or within a family. This diversity can be explained by the localization of the adenomatous polyposis coli (APC) variant, but few reports provide definitive findings about genotype-phenotype correlations. Therefore, we investigated FAP patients and the association between the severe phenotypes and APC variants. Of 247 FAP patients, 126 patients from 85 families identified to have APC germline variant sites were extracted. These sites were divided into six groups (Regions A to F), and the frequency of severe comorbidities was compared among the patient phenotypes. Of the 126 patients, the proportions of patients with desmoid tumor stage ≥III, number of FGPs ≥1000, multiple gastric neoplasms, gastric neoplasm with high-grade dysplasia, and Spigelman stage ≥III were 3%, 16%, 21%, 12%, and 41%, respectively, while the corresponding rates were 30%, 50%, 70%, 50%, and 80% in patients with Region E (codons 1398-1580) variants. These latter rates were significantly higher than those for patients with variants in other regions. Moreover, the proportion of patients with all three indicators (desmoid tumor stage ≥III, number of FGPs ≥1000, and Spigelman stage ≥III) was 20% for those with variants in Region E and 0% for those with variants in other regions. Variants in Region E indicate aggressive phenotypes, and more intensive management is required.
家族性腺瘤性息肉病(FAP)患者会出现各种危及生命的结肠外合并症,这些合并症单独或在家族中出现。这种多样性可以通过腺瘤性结肠息肉病(APC)变异的定位来解释,但很少有报告提供关于基因型-表型相关性的明确发现。因此,我们研究了 FAP 患者以及严重表型与 APC 变异之间的关联。在 247 名 FAP 患者中,从 85 个家族中提取出了 126 名具有 APC 种系变异位点的患者。这些位点被分为六个组(区域 A 至 F),并比较了患者表型之间严重合并症的频率。在 126 名患者中,III 期以上的硬纤维瘤、FGPs 数≥1000、多发性胃息肉、高级别不典型增生的胃息肉和 Spigelman 分期≥III 的患者比例分别为 3%、16%、21%、12%和 41%,而区域 E(密码子 1398-1580)变异患者的相应比例分别为 30%、50%、70%、50%和 80%。后一组的比例明显高于其他区域变异患者。此外,在区域 E 变异的患者中,有三个指标(硬纤维瘤 III 期以上、FGPs 数≥1000 和 Spigelman 分期≥III)的患者比例为 20%,而在其他区域变异的患者中则为 0%。区域 E 的变异提示侵袭性表型,需要更强化的管理。